A Phase 3, Multicenter, Open-Label, Two-Part Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Depot Formulation in Children With Central Precocious Puberty (CPP)
Phase of Trial: Phase III
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs Leuprorelin (Primary)
- Indications Precocious puberty
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 18 Oct 2019 Planned End Date changed from 1 Nov 2022 to 29 May 2023.
- 26 Oct 2018 Status changed from not yet recruiting to recruiting.
- 11 Oct 2018 New trial record